SCHEMBL2190955

SCHEMBL2190955

CN1CCN(c2ccnc(Cl)n2)CC1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 8/20 0.65
HRH3 Q9Y5N1 2/20 0.65
HTR3A P46098 3/20 0.57
HTR3E A5X5Y0 2/20 0.57
HTR3B O95264 2/20 0.57
HTR3D Q70Z44 2/20 0.57
HTR3C Q8WXA8 2/20 0.57
ALDH1A1 P00352 3/20 0.54
CYP1A2 P05177 3/20 0.54
HSD17B10 Q99714 3/20 0.54
CYP2D6 P10635 2/20 0.54
ALOX15 P16050 1/20 0.54
CYP3A4 P08684 2/20 0.52
CLK4 Q9HAZ1 2/20 0.52
USP2 O75604 1/20 0.52
CASP1 P29466 1/20 0.52
CASP7 P55210 1/20 0.52
TSHR P16473 1/20 0.52
HTR6 P50406 1/20 0.52
TRPV1 Q8NER1 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29997962 1.00 HRH4 (0.65) HRH4HRH3HTR3AHTR3EHTR3B
SCHEMBL3949154 0.83 TRPV1 (0.51) HRH4HRH3CYP1A2TRPV1SORD
SCHEMBL1427479 0.83 TRPV1 (0.51) HRH4HRH3TRPV1SORD
SCHEMBL29519276 0.83 TRPV1 (0.51) HRH4HRH3CYP1A2TRPV1SORD
SCHEMBL2087838 0.81 CXCR4 (0.51) HRH4HRH3CYP1A2TRPV1SORD
SCHEMBL1088796 0.81 CXCR4 (0.51) HRH4HRH3CYP1A2TRPV1SORD
SCHEMBL15260204 0.81 HRH3 (0.51) HRH4HRH3TRPV1SORD
SCHEMBL8475763 0.81 HRH4 (0.63) HRH4HRH3HTR3AHTR3EHTR3B
SCHEMBL28219653 0.80 TRPV1 (0.49) HRH4HRH3TRPV1SORD
SCHEMBL14029975 0.80 HRH4 (0.67) HRH4HRH3HTR3AHTR3EHTR3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4602041-A1 HPK1 INHIBITORS AND METHODS OF USE THEREOF Arcus Biosciences, Inc. (US) 2025-08-20 EP disclosed
CN-108135175-B Bicyclic compounds and their use for inhibition of SUV39H2 肿瘤疗法科学股份有限公司 2021-04-06 CN disclosed
EP-3355699-B1 BICYCLIC COMPOUND AND USE THEREOF FOR INHIBITING SUV39H2 ONCOTHERAPY SCIENCE INC (JP) 2021-03-31 EP disclosed
EP-3565810-A1 PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION ViiV Healthcare UK (No.5) Limited (GB) 2019-11-13 EP disclosed
US-20180273529-A1 BICYCLIC COMPOUND AND USE THEREOF FOR INHIBITING SUV39H2 ONCOTHERAPY SCIENCE, INC. (JP) 2018-09-27 US disclosed
EP-3355699-A1 BICYCLIC COMPOUND AND USE THEREOF FOR INHIBITING SUV39H2 OncoTherapy Science, Inc. (JP) 2018-08-08 EP disclosed
WO-2018127801-A1 PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV Healthcare UK (No.5) Limited (GB) 2018-07-12 WO disclosed
CN-101687863-B Amino-thiazolyl-pyrimidine derivatives and their use to treat cancer ASTRAZENECA AB 2012-09-12 CN disclosed
US-8022209-B2 Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor JANSSEN PHARMACEUTICA NV (BE) 2011-09-20 US disclosed
US-20110172241-A1 Benzazole analogues and uses thereof 4SC AG (DE) 2011-07-14 US disclosed
US-7576090-B2 e.g. N-[2-(6,7-Dimethoxyquinazolin-4-ylamino)benzothiazol-6-yl ]benzamide; multi-target protein kinase, especially epidermal and endothrlial growth factor, inhibitors; antiproliferative, anticarcinogenic agent 4SC AG (DE) 2009-08-18 US disclosed
WO-2009035671-A1 SUBSTITUTED NITROGEN-CONTAINING HETEROARYL DERIVATIVES USEFUL AS MODULATORS OF THE HISTAMINE H4 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2009-03-19 WO disclosed
US-20090069305-A1 Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor JANSSEN PHARMACEUTICA N.V. (BE) 2009-03-12 US disclosed
EP-1910349-A1 2-ARYLBENZOTHIAZOLES AND USES THEREOF 4SC AG (DE) 2008-04-16 EP disclosed
WO-2007009524-A1 2-ARYLBENZOTHIAZOLES AND USES THEREOF 4SC AG (DE) 2007-01-25 WO disclosed
US-20070021446-A1 2-arylbenzothiazole analogues and uses thereof 4SC AG (DE) 2007-01-25 US disclosed
EP-1746096-A1 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer 4SC AG (DE) 2007-01-24 EP disclosed
US-20060142570-A1 Benzazole analogues and uses thereof 4SC AG (DE) 2006-06-29 US disclosed
WO-2004074287-A1 NOVEL COMPOUNDS ASTRAZENECA AB (SE) 2004-09-02 WO disclosed
WO-2004074278-A1 NOVEL COMPOUNDS ASTRAZENECA AB (SE) 2004-09-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180273529-A1 BICYCLIC COMPOUND AND USE THEREOF FOR INHIBITING SUV39H2 SUV39H2, SUV39H1, EZH1 HRH4 511/4885HRH3 199/4885HTR3A 4225/4885
US-20060142570-A1 Benzazole analogues and uses thereof CYP3A5, CYP3A7, CYP3A43 HRH4 1342/4885HRH3 1910/4885HTR3A 692/4885
US-20070021446-A1 2-arylbenzothiazole analogues and uses thereof NR2E1, NR2E3, NR0B2 HRH4 2379/4885HRH3 2710/4885HTR3A 1081/4885
US-20110172241-A1 Benzazole analogues and uses thereof CYP3A5, CYP3A7, CYP3A43 HRH4 1342/4885HRH3 1910/4885HTR3A 692/4885
US-20090069305-A1 Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor HRH4, HRH3, HRH2 HRH4 1/4885HRH3 2/4885HTR3A 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.